用于T细胞恶性肿瘤的即用型CD2通用CAR-T疗法
研究开发了敲除CD2以防止自相残杀、去除T细胞受体以防止移植物抗宿主病的同种异体通用CD2靶向CAR-T细胞(UCART2),其在体内对T-ALL和CTCL显示疗效并延长荷瘤NSG小鼠生存;CD2缺失会降低CAR-T功能,但联用长效重组人白细胞介素-7(rhIL-7-hyFc)可逆转该效应并延长UCART2持续性及生存。
要点
- UCART2在体内对T-ALL和CTCL显示疗效并延长荷瘤NSG小鼠生存。
- CD2缺失降低UCART19效应细胞因子频率及抗肿瘤疗效。
- 联用rhIL-7-hyFc可逆转CD2缺失所致疗效降低并延长UCART2持续性。
核心结论
- 同种异体抗自相残杀UCART2联合rhIL-7-hyFc可能是治疗T细胞恶性肿瘤的合适方法。
研究设计与样本
- 研究开发了同种异体通用CD2靶向CAR-T细胞(UCART2),敲除CD2以防止自相残杀,去除T细胞受体以防止移植物抗宿主病。
- 研究在体内使用肿瘤移植NSG小鼠、CD19+ NALM6异种移植模型、肿瘤再攻击模型和原发患者T-ALL模型进行评价。
- 研究通过单细胞分泌组分析比较了CD2缺失与未缺失的UCART19。
主要发现
- UCART2在体内对T-ALL和CTCL显示疗效并延长肿瘤移植NSG小鼠的生存。
- 单细胞分泌组分析显示,UCART19中CD2缺失降低了效应细胞因子(颗粒酶-B和IFN-γ)的频率。
- 在CD19+ NALM6异种移植模型中,UCART19ΔCD2较UCART19抗肿瘤疗效降低。
- CD2缺失所致的疗效降低在联用rhIL-7-hyFc(长效重组人白细胞介素-7)时被逆转。
- rhIL-7-hyFc治疗在肿瘤再攻击模型和原发患者T-ALL体内模型中均延长UCART2持续性并提高生存。
关键数值与推荐
- UCART2靶向CD2,CD2抗原被删除以防止自相残杀,T细胞受体被去除以防止GvHD。
- CD2缺失降低UCART19中颗粒酶-B和IFN-γ的效应细胞因子频率。
- rhIL-7-hyFc为长效重组人白细胞介素-7。
临床怎么用
- 作者认为,同种异体抗自相残杀UCART2联合rhIL-7-hyFc可能是治疗T细胞恶性肿瘤的合适方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To broaden the use of CAR-T cells in pan T-cell malignancies, we developed an allogeneic "universal" CD2-targeting CAR-T cell (UCART2), in which the CD2 antigen is deleted to prevent fratricide, and the T-cell receptor is removed to prevent GvHD. UCART2 demonstrated efficacy against T-ALL and CTCL and prolonged the survival of tumor-engrafted NSG mice in vivo. To evaluate the impact of CD2 on CAR-T function, we generated CD19 CAR-T cells (UCART19) with or without CD2 deletion, single-cell secretome analysis revealed that CD2 deletion in UCART19 reduced frequencies of the effector cytokines (Granzyme-B and IFN-γ). We also observed that UCART19ΔCD2 had reduced anti-tumor efficacy compared to UCART19 in a CD19+NALM6 xenograft model. Of note is that the reduced efficacy resulting from CD2 deletion was reversed when combined with rhIL-7-hyFc, a long-acting recombinant human interleukin-7. Treatment with rhIL-7-hyFc prolonged UCART2 persistence and increased survival in both the tumor re-challenge model and primary patient T-ALL model in vivo. Together, these data suggest that allogeneic fratricide-resistant UCART2, in combination with rhIL-7-hyFc, could be a suitable approach for treating T-cell malignancies.
引用
- Xiang J, Devenport JM, Carter AJ, et al. An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies. Leukemia. 2023. PMID: 37798328. doi:10.1038/s41375-023-02039-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。